4-Fluorocyclohexanecarbaldehyde | 1554041-53-0

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代烷
• 英文名称: 4-Fluorocyclohexanecarbaldehyde
• 英文别名: 4-fluorocyclohexane-1-carbaldehyde
• CAS: 1554041-53-0
• 化学式: C₇H₁₁FO
• 分子量: 130.16
• InChiKey: OQRSBWCLDGFKRY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE<br/>[FR] COMPOSÉS DE FLUORO-PERHEXILINE ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：UNIV ABERDEEN

  公开号：WO2014184561A1

  公开（公告）日：2014-11-20

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain fluoro-perhexiline compounds of the following formula (also referred to herein as FPER compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, for example, those which are known to be treated with, or known to be treatable with, perhexiline, including, for example, disorders that are ameliorated by the inhibition of carnitine palmitoyltransferase (CPT); cardiovascular disorders such as: angina pectoris; heart failure (HF); ischaemic heart disease (IHD); cardiomyopathy; cardiac dysrhythmia; stenosis of a heart valve; hypertrophic cardiomyopathy (HCM); coronary heart disease; and other disorders, for example, diabetes and cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及以下式（在本文中也称为FPER化合物）的某些氟代perhexiline化合物，例如用于治疗包括已知可用perhexiline治疗或已知可用perhexiline治疗的紊乱（例如疾病），包括通过抑制肉碱棕榈酰基转移酶（CPT）改善的紊乱，如：心绞痛；心力衰竭（HF）；缺血性心脏病（IHD）；心肌病；心脏心律失常；心脏瓣膜狭窄；肥厚型心肌病（HCM）；冠心病；以及其他疾病，例如糖尿病和癌症。本发明还涉及包括这些化合物的药物组合物，以及这些化合物和组合物的用途，例如在治疗中的用途。
• FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE
  申请人：THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN

  公开号：US20160102058A1

  公开（公告）日：2016-04-14

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain fluoro-perhexiline compounds of the following formula (also referred to herein as FPER compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, for example, those which are known to be treated with, or known to be treatable with, perhexiline, including, for example, disorders that are ameliorated by the inhibition of carnitine palmitoyltransferase (CPT); cardiovascular disorders such as: angina pectoris; heart failure (HF); ischaemic heart disease (IHD); cardiomyopathy; cardiac dysrhythmia; stenosis of a heart valve; hypertrophic cardiomyopathy (HCM); coronary heart disease; and other disorders, for example, diabetes and cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

  本发明一般涉及治疗化合物领域。更具体地，本发明涉及下列公式的某些氟代perhexiline化合物（在此称为FPER化合物），例如用于治疗障碍（例如疾病），包括那些已知可以用perhexiline治疗或可以用perhexiline治疗的障碍，包括例如通过抑制肉碱棕榈酰转移酶（CPT）改善的障碍：心绞痛，心力衰竭（HF），缺血性心脏病（IHD），心肌病，心脏心律失常，心脏瓣膜狭窄，肥厚型心肌病（HCM），冠心病以及其他障碍，例如糖尿病和癌症。本发明还涉及包含这些化合物的制药组合物，以及这些化合物和组合物的使用，例如在治疗中的使用。
• Cyclohexyldioxane
  申请人：MERCK PATENT GmbH

  公开号：EP0135062A2

  公开（公告）日：1985-03-27

  Verbindungen der Formel I worin R eine Alkylgruppe mit bis zu 12 C-Atomen, wobie 1 oder 2 CH2-Gruppen durch 0-Atome ersetzt sein können, X CN, F, Cl oder Br, Dio eine 1,3-Dioxan-2,5-diylgruppe und Cy eine 1,4-Cyclohexylengruppe bedeuten eignen sich zur Verwendung als Komponenten flüssigkristalliner Dielektrika.

  式 I 的化合物 其中 R 是最多具有 12 个碳原子的烷基，其中 1 或 2 个 CH2 基团可被 0 原子取代、 X 是 CN、F、Cl 或 Br、 Dio 是 1,3-二氧六环-2,5-二基，以及 Cy 是 1,4-环己烯基团 适合用作液晶电介质的成分。
• Fluorine-labeled compounds
  申请人：De Jesus Omayra Padilla

  公开号：US20080139787A1

  公开（公告）日：2008-06-12

  Methods for introducing fluorine atom onto a polypeptide are provided. Also provided are linkers, bioconjugates, and bifunctional compound agents made using the methods, linkers, and bioconjugates. The methods comprise: (i) providing a linker comprising a thiol-reactive terminus and an aldehyde-reactive terminus; (ii) reacting the thiol-reactive terminus of the linker with a polypeptide comprising at least one thiol group or a reactive derivative thereof; and (iii) subsequently reacting the aldehyde-reactive terminus of the linker with a fluorine-substituted aldehyde.
• PDGF-RBeta BINDERS
  申请人：Marino Michael Ernest

  公开号：US20090191124A1

  公开（公告）日：2009-07-30

  Provided herein are PDGF-Rβ imaging agents that are polypeptides labeled with a signal generator (e.g., paramagnetic label, a radionuclide, or a fluorophore), wherein the imaging agents bind specifically to PDGFR-β. Also provided are in vivo imaging methods using the imaging agents.